In this European Pharmaceutical Manufacturer Magazine opinion article, MDCPartners’ founder and CEO, Mireille De Cré, explains how pharma R&D can make the most of the big data revolution.

The big data hype train has been gaining momentum for a number of years and its rise has been well documented. However, pharma companies are still perplexed by the scope of what big data can do, and why, how and where they should use big data tools to their advantage.

With focus moving away from sheer volume of data and inherent variability and complexity of large unstructured datasets towards user-friendly analytic tools that can help businesses plan for the future, now is the time for big, small and medium size pharma to seize the ‘big data’ opportunity.

What is clear is that big data is here to stay and will continue to have a growing influence in terms of its impact to business decision making across a number of sectors. Some of those in pharma are firmly grasping the opportunity that analytics-based decision making can bring… And those that aren’t will need to catch up before they lose out.

Read more in the European Pharmaceutical Manufacturer Magazine article: http://www.epmmagazine.com/opinion/big-data/

Share on:
Tweet about this on TwitterShare on LinkedIn